Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VKTX

VKTX - Viking Therapeutics Inc Stock Price, Fair Value and News

$30.42-0.98 (-3.12%)
Market Closed

Price Targets

VKTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VKTX Price Action

Last 7 days

-8.9%

Last 30 days

-16.6%

Last 90 days

-20.3%

Trailing 12 Months

-11.4%

VKTX RSI Chart

VKTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VKTX Valuation

Market Cap

3.4B

Price/Earnings (Trailing)

-14.41

Price/Free Cashflow

-15.23

VKTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

VKTX Fundamentals

VKTX Earnings

Earnings (TTM)

-237.4M

Earnings Growth (Yr)

-264.02%

Earnings Growth (Qtr)

-38.48%

VKTX Profitability

Return on Equity

-33.29%

Return on Assets

-32.11%

Free Cashflow Yield

-6.57%

VKTX Investor Care

Shares Dilution (1Y)

1.39%

Diluted EPS (TTM)

-2.12

VKTX Alerts

  • 4 major insider sales recently.

About Viking Therapeutics Inc

VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
 CEO
 WEBSITEvikingtherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES22

Viking Therapeutics Inc Frequently Asked Questions

VKTX is the stock ticker symbol of Viking Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Viking Therapeutics Inc is 3.42 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check VKTX's fair value in chart for subscribers.

The fair value guage provides a quick view whether VKTX is over valued or under valued. Whether Viking Therapeutics Inc is cheap or expensive depends on the assumptions which impact Viking Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VKTX.

In the past 10 years, Viking Therapeutics Inc has provided 0.308 (multiply by 100 for percentage) rate of return.